Arteris, Inc. ((AIP)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arteris, Inc. struck an upbeat tone on its latest earnings call, highlighting robust top‑line growth, record recurring metrics, and strengthening cash generation alongside a clear route to profitability by 2026. Management acknowledged ongoing GAAP and non‑GAAP losses and some one‑time royalty and acquisition noise, but framed these as manageable trade‑offs against accelerating demand and a widening technology footprint.
Revenue Growth and Beat
Arteris reported Q4 revenue of $20.1 million, up 16% sequentially and 30% year over year, topping the high end of guidance and underscoring strong demand for its IP. For the full year 2025, revenue reached $70.6 million, a 22% increase, signaling durable momentum even before the contribution from the newly acquired Cycuity business.
Record ACV, Royalties and Backlog
Annual contract value plus royalties climbed to a record $83.6 million, up 28% year over year, underscoring the strength of Arteris’ subscription‑like model. Remaining performance obligations rose 32% to $117.0 million, giving the company a sizable contracted backlog to convert into future revenue.
Royalty Engine Accelerates
Variable royalties surged roughly 50% year over year, with Q4 setting a new record as more chips using Arteris IP hit volume production. The number of large six‑figure‑plus royalty payers expanded to nine from just one five years ago, suggesting a broader and more resilient royalty base over time.
High Margins and Better Operating Leverage
Non‑GAAP gross margin held at an impressive 92% in Q4 and for the full year, confirming the attractive economics of the IP licensing model. Operating expense growth on a non‑GAAP basis was limited to 14%, roughly half the pace of revenue growth, driving an eight‑point improvement in non‑GAAP operating margin versus last year.
Cash Generation and Balance Sheet Strength
The company closed 2025 with $59.5 million in cash and equivalents and no financial debt, providing a solid liquidity cushion. Free cash flow turned positive, reaching $3.0 million in Q4 and $5.3 million for the year, near the top end of management’s guidance range.
Expanding Product Adoption and Ecosystem Wins
Arteris’ FlexNoC interconnect IP has now been licensed for more than 30 production device deployments, while Ncore and other offerings gained traction with major names such as NXP, AMD, Altera, Blaize, and Black Sesame. Customers have collectively shipped over 4 billion chips and chiplets using the company’s IP, reinforcing its relevance in complex semiconductor designs.
Cycuity Deal Broadens Security Footprint
The recently closed Cycuity acquisition adds hardware‑security assurance tools that expand Arteris’ addressable market into safety‑ and security‑critical applications. Management expects Cycuity to contribute about $7 million of revenue in 2026 and to unlock cross‑sell opportunities across both existing and new semiconductor customers.
GAAP Losses Still Material
Despite the operational progress, Arteris remains in the red on a GAAP basis, posting a Q4 GAAP operating loss of $8.5 million and a full‑year loss of $33.1 million. GAAP net loss for 2025 totaled $34.7 million, or a diluted loss per share of $0.82, underscoring that profitability is still a medium‑term goal.
Non‑GAAP Losses Narrowing
On a non‑GAAP basis, the operating loss narrowed to $2.2 million in Q4 and $12.5 million for 2025, an improvement of $2.4 million from the prior year. Non‑GAAP net loss for the year was $14.1 million, or $0.33 per share, indicating that Arteris is moving toward break‑even but has not yet reached sustained profitability.
Royalty Boost Includes One‑Off Element
Management flagged that Q4 royalties benefited from a specific pickup of under $0.5 million, stemming from audit and timing factors. While not changing the broader royalty growth story, this one‑time benefit means investors should avoid extrapolating Q4’s royalty run‑rate in a straight line.
Cycuity’s Near‑Term Drag and Margin Effects
Cycuity is expected to modestly increase Arteris’ 2026 non‑GAAP loss by about $1 million and to create roughly $1 million of negative free cash flow for the year, concentrated in the first quarter. In addition, certain government‑related subcontractor costs will be classified in a way that could trim reported gross margin by around one to two percentage points.
Revenue Timing and Backlog Conversion Risk
Arteris plans to recognize only around half of its $117 million of remaining performance obligations as 2026 revenue, excluding cancelable items. This introduces some timing uncertainty for investors, as the pace of converting contracted backlog into recognized revenue may vary by project and customer.
Equity Raise Overhang
The company has established an at‑the‑market equity program to rebuild cash spent on the Cycuity deal and expects only modest issuance early in the year. However, the timing and size of any share sales remain unclear, leaving a potential overhang from future dilution and funding execution risk.
Guidance and Path Toward Profitability
For Q1 2026, Arteris guided ACV plus royalties to $85–89 million, revenue to $20.5–21.5 million, a non‑GAAP operating loss of $3.5–2.5 million, and non‑GAAP free cash flow between a $1.5 million outflow and a $1.5 million inflow. For full‑year 2026, it expects ACV plus royalties exiting the year at $100–104 million, revenue of $89–93 million, a narrowed non‑GAAP operating loss of $9–5 million, and free cash flow of $5–9 million, reinforcing its ambition to achieve non‑GAAP operating profitability as early as 2026.
Arteris’ latest earnings call painted a picture of a high‑margin IP business gaining commercial scale, with royalties and contracted backlog pointing to stronger years ahead. While GAAP losses, integration costs from Cycuity, revenue timing, and equity issuance risk still cloud the near term, the company’s accelerating growth and improving cash profile will likely keep it on investors’ radar.

